YAP is a critical oncogene in human cholangiocarcinoma

Oncotarget

Volumn 6, Issue 19, 2015, Pages 17206-17220

  Pei, Tiemin ^a   Li, Yuejin ^a   Wang, Jiabei ^a   Wang, Huanlai ^a,b   Liang, Yingjian ^a   Shi, Huawen ^a   Sun, Boshi ^a   Yin, Dalong ^a   Sun, Jing ^a   Song, Ruipeng ^a   Pan, Shangha ^a   Sun, Yu ^a   Jiang, Hongchi ^a   Zheng, Tongsen ^a   Liu, Lianxin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b Qiqihaer City Hospital of Traditional Chinese Medicine   (China)

Author keywords

AKT; Cholangiocarcinoma; Gankyrin; Tumorigenesis; YAP

Indexed keywords

MICRORNA; MICRORNA 29C; PROTEIN KINASE B; SHORT HAIRPIN RNA; SOMATOMEDIN C; UNCLASSIFIED DRUG; ONCOPROTEIN; PHOSPHOPROTEIN; PROTEASOME; PSMD10 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT CARCINOMA; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; CARCINOMA CELL LINE; CELL MIGRATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; ONCOGENE; TUMOR INVASION; TUMOR PROMOTION; YAP GENE; ANIMAL; BAGG ALBINO MOUSE; BILE DUCT TUMOR; BIOSYNTHESIS; CELL TRANSFORMATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; KAPLAN MEIER METHOD; MORTALITY; PATHOLOGY; TISSUE MICROARRAY; TUMOR CELL LINE; UPREGULATION; WESTERN BLOTTING; XENOGRAFT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BILE DUCT NEOPLASMS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CHOLANGIOCARCINOMA; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL-MESENCHYMAL TRANSITION; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; KAPLAN-MEIER ESTIMATE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; PHOSPHOPROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS; TISSUE ARRAY ANALYSIS; UP-REGULATION;

EID: 84938228705     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4043     Document Type: Article

References (49)

1. Malhi H and Gores GJ. Cholangiocarcinoma: modern advances in understanding a deadly old disease. Journal of hepatology. 2006; 45:856-867.
2. Khan SA, Thomas HC, Davidson BR and Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005; 366:1303-1314.
3. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P and Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. Journal of hepatology. 2002; 37:806-813.
4. Lau SH and Lau WY. Current therapy of hilar cholangiocarcinoma. Hepatobiliary & pancreatic diseases international : HBPD INT. 2012; 11:12-17.
5. Romiti A, D'Antonio C, Zullo A, Sarcina I, Di Rocco R, Barucca V, Durante V and Marchetti P. Chemotherapy for the biliary tract cancers: moving toward improved survival time. Journal of gastrointestinal cancer. 2012; 43:396-404.
6. Liu AM, Xu MZ, Chen J, Poon RT and Luk JM. Targeting YAP and Hippo signaling pathway in liver cancer. Expert opinion on therapeutic targets. 2010; 14:855-868.
7. Komuro A, Nagai M, Navin NE and Sudol M. WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. The Journal of biological chemistry. 2003; 278:33334-33341.
8. Zaidi SK, Sullivan AJ, Medina R, Ito Y, van Wijnen AJ, Stein JL, Lian JB and Stein GS. Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. The EMBO journal. 2004; 23:790-799.
9. Lapi E, Di Agostino S, Donzelli S, Gal H, Domany E, Rechavi G, Pandolfi PP, Givol D, Strano S, Lu X and Blandino G. PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Molecular cell. 2008; 32:803-814.
10. Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu J, Lin JD, Wang CY, Chinnaiyan AM, Lai ZC and Guan KL. TEAD mediates YAP-dependent gene induction and growth control. Genes & development. 2008; 22:1962-1971.
11. Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, Lowe SW, Poon RT and Luk JM. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer. 2009; 115:4576-4585.
12. Fernandez LA, Northcott PA, Dalton J, Fraga C, Ellison D, Angers S, Taylor MD and Kenney AM. YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. Genes & development. 2009; 23:2729-2741.
13. Steinhardt AA, Gayyed MF, Klein AP, Dong J, Maitra A, Pan D, Montgomery EA and Anders RA. Expression of Yes-associated protein in common solid tumors. Human pathology. 2008; 39:1582-1589.
14. Li SY, Hu JA and Wang HM. Expression of Yes-associated protein 1 gene and protein in oral squamous cell carcinoma. Chinese medical journal. 2013; 126:655-658.
15. Hall CA, Wang R, Miao J, Oliva E, Shen X, Wheeler T, Hilsenbeck SG, Orsulic S and Goode S. Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer research. 2010; 70:8517-8525.
16. Liu JY, Li YH, Lin HX, Liao YJ, Mai SJ, Liu ZW, Zhang ZL, Jiang LJ, Zhang JX, Kung HF, Zeng YX, Zhou FJ and Xie D. Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder. BMC cancer. 2013; 13:349.
17. Kang W, Tong JH, Chan AW, Lee TL, Lung RW, Leung PP, So KK, Wu K, Fan D, Yu J, Sung JJ and To KF. Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011; 17:2130-2139.
18. Lee KW, Lee SS, Kim SB, Sohn BH, Lee HS, Jnag HJ, Park YY, Kopetz S, Kim SS, Oh SC and Lee JS. Significant Association of oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014.
19. Song R, Song H, Liang Y, Yin D, Zhang H, Zheng T, Wang J, Lu Z, Song X, Pei T, Qin Y, Li Y, Xie C, et al. Reciprocal activation between ATPase inhibitory factor 1 and NF-kappaB drives hepatocellular carcinoma angiogenesis and metastasis. Hepatology. 2014; 60:1659-1673.
20. Wang Y, Dong Q, Zhang Q, Li Z, Wang E and Qiu X. Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer science. 2010; 101:1279-1285.
21. Perra A, Kowalik MA, Ghiso E, Ledda-Columbano GM, Di Tommaso L, Angioni MM, Raschioni C, Testore E, Roncalli M, Giordano S and Columbano A. YAP activation is an early event and a potential therapeutic target in liver cancer development. Journal of hepatology. 2014.
22. Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y, Lauwers GY, Thasler W, Lee JT, Avruch J and Bardeesy N. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer cell. 2009; 16:425-438.
23. Li S, Han Z, Ma Y, Song R, Pei T, Zheng T, Wang J, Xu D, Fang X, Jiang H and Liu L. Hydroxytyrosol inhibits cholangiocarcinoma tumor growth: an in vivo and in vitro study. Oncology reports. 2014; 31:145-152.
24. Tao J, Calvisi DF, Ranganathan S, Cigliano A, Zhou L, Singh S, Jiang L, Fan B, Terracciano L, Armeanu-Ebinger S, Ribback S, Dombrowski F, Evert M, et al. Activation of beta-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice. Gastroenterology. 2014; 147:690-701.
25. Li H, Wolfe A, Septer S, Edwards G, Zhong X, Abdulkarim AB, Ranganathan S and Apte U. Deregulation of Hippo kinase signalling in human hepatic malignancies. Liver international : official journal of the International Association for the Study of the Liver. 2012; 32:38-47.
26. Lau AN, Curtis SJ, Fillmore CM, Rowbotham SP, Mohseni M, Wagner DE, Beede AM, Montoro DT, Sinkevicius KW, Walton ZE, Barrios J, Weiss DJ, Camargo FD, et al. Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis. The EMBO journal. 2014; 33:468-481.
27. Wang L, Shi S, Guo Z, Zhang X, Han S, Yang A, Wen W and Zhu Q. Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells. PloS one. 2013; 8:e65539.
28. Ge L, Smail M, Meng W, Shyr Y, Ye F, Fan KH, Li X, Zhou HM and Bhowmick NA. Yes-associated protein expression in head and neck squamous cell carcinoma nodal metastasis. PloS one. 2011; 6:e27529.
29. Chen D, Sun Y, Wei Y, Zhang P, Rezaeian AH, Teruya-Feldstein J, Gupta S, Liang H, Lin HK, Hung MC and Ma L. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nature medicine. 2012; 18:1511-1517.
30. Thiery JP, Acloque H, Huang RY and Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009; 139:871-890.
31. Zheng T, Hong X, Wang J, Pei T, Liang Y, Yin D, Song R, Song X, Lu Z, Qi S, Liu J, Sun B, Xie C, et al. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma. Hepatology. 2014; 59:935-946.
32. Dong LW, Yang GZ, Pan YF, Chen Y, Tan YX, Dai RY, Ren YB, Fu J and Wang HY. The oncoprotein p28GANK establishes a positive feedback loop in beta-catenin signaling. Cell research. 2011; 21:1248-1261.
33. Xu MZ, Chan SW, Liu AM, Wong KF, Fan ST, Chen J, Poon RT, Zender L, Lowe SW, Hong W and Luk JM. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene. 2011; 30:1229-1240.
34. Tumaneng K, Schlegelmilch K, Russell RC, Yimlamai D, Basnet H, Mahadevan N, Fitamant J, Bardeesy N, Camargo FD and Guan KL. YAP mediates crosstalk between the Hippo and PI(3)K-TOR pathways by suppressing PTEN via miR-29. Nature cell biology. 2012; 14:1322-1329.
35. Xin M, Kim Y, Sutherland LB, Qi X, McAnally J, Schwartz RJ, Richardson JA, Bassel-Duby R and Olson EN. Regulation of insulin-like growth factor signaling by Yap governs cardiomyocyte proliferation and embryonic heart size. Science signaling. 2011; 4:ra70.
36. Dorn GW, 2nd and Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. The Journal of clinical investigation. 2005; 115:527-537.
37. Zhao B, Li L, Tumaneng K, Wang CY and Guan KL. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes & development. 2010; 24:72-85.
38. Wang J, Park JS, Wei Y, Rajurkar M, Cotton JL, Fan Q, Lewis BC, Ji H and Mao J. TRIB2 acts downstream of Wnt/TCF in liver cancer cells to regulate YAP and C/EBPalpha function. Molecular cell. 2013; 51:211-225.
39. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, Zheng P, Ye K, Chinnaiyan A, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes & development. 2007; 21:2747-2761.
40. Bertini E, Oka T, Sudol M, Strano S and Blandino G. YAP: at the crossroad between transformation and tumor suppression. Cell cycle. 2009; 8:49-57.
41. Avruch J, Zhou D, Fitamant J and Bardeesy N. Mst1/2 signalling to Yap: gatekeeper for liver size and tumour development. British journal of cancer. 2011; 104:24-32.
42. Vidal M and Cagan RL. Drosophila models for cancer research. Current opinion in genetics & development. 2006; 16:10-16.
43. Huo X, Zhang Q, Liu AM, Tang C, Gong Y, Bian J, Luk JM, Xu Z and Chen J. Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinoma. Oncology reports. 2013; 29:840-846.
44. Mayer RJ and Fujita J. Gankyrin, the 26 S proteasome, the cell cycle and cancer. Biochemical Society transactions. 2006; 34:746-748.
45. Higashitsuji H, Itoh K, Nagao T, Dawson S, Nonoguchi K, Kido T, Mayer RJ, Arii S and Fujita J. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nature medicine. 2000; 6:96-99.
46. Park TJ, Kim HS, Byun KH, Jang JJ, Lee YS and Lim IK. Sequential changes in hepatocarcinogenesis induced by diethylnitrosamine plus thioacetamide in Fischer 344 rats: induction of gankyrin expression in liver fibrosis, pRB degradation in cirrhosis, and methylation of p16(INK4A) exon 1 in hepatocellular carcinoma. Molecular carcinogenesis. 2001; 30:138-150.
47. Ortiz CM, Ito T, Tanaka E, Tsunoda S, Nagayama S, Sakai Y, Higashitsuji H, Fujita J and Shimada Y. Gankyrin oncoprotein overexpression as a critical factor for tumor growth in human esophageal squamous cell carcinoma and its clinical significance. International journal of cancer Journal international du cancer. 2008; 122:325-332.
48. Zhen C, Chen L, Zhao Q, Liang B, Gu YX, Bai ZF, Wang K, Xu X, Han QY, Fang DF, Wang SX, Zhou T, Xia Q, et al. Gankyrin promotes breast cancer cell metastasis by regulating Rac1 activity. Oncogene. 2013; 32:3452-3460.
49. Moe IT, Pham TA, Hagelin EM, Ahmed MS and Attramadal H. CCN2 exerts direct cytoprotective actions in adult cardiac myocytes by activation of the PI3-kinase/Akt/GSK-3beta signaling pathway. Journal of cell communication and signaling. 2013; 7:31-47.